DOCSLIB.ORG

FLUOROQUINOLONES: from Structure to Activity and Toxicity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FLUOROQUINOLONES: from Structure to Activity and Toxicity FLUOROQUINOLONES: from structure to activity and toxicity F. Van Bambeke, Pharm. D. & P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université Catholique de Louvain, Brussels, Belgium SBIMC / BVIKM www.sbimc.org - www.bvikm.org www.md.ucl.ac.be/facm www.isap.org soon... Mechanism of action of fluoroquinolones: the basics... PORIN DNA Topo DNA gyrase isomerase Gram (-) Gram (+) 2 key enzymes in DNA replication: DNA gyrase topoisomerase IV bacterial DNA is supercoiled Ternary complex DNA - enzyme - fluoroquinolone DNA GYRASE catalytic subunits COVALENTLY CLOSED CIRCULAR DNA FLUOROQUINOLONES: DNA GYRASE ATP binding subunits 4 stacked molecules (Shen, in Quinolone Antimicrobial Agents, 1993) Resistance to fluoroquinolones: the basics decreased efflux pump permeability DNA mutation of DNA gyrase Topo isomerase the enzymes Gram (-) Gram (+) Fluoroquinolones are the first entirely man-made antibiotics: do we understand our molecule ? R5 O R COOH 6 R7 X8 N R1 Don’t panic, we will travel together…. Chemistry and Activity This is where all begins... The pharmacophore common to all fluoroquinolones BINDING TO DNA R5 O O R C 6 - BINDING TO O BINDING TO THE ENZYME THE ENZYME R7 X8 N R1 AUTO-ASSEMBLING DOMAIN (for stacking) From chloroquine to nalidixic acid... nalidixic acid N CH3 O O HN CH 3 C - O chloroquine CH N N Cl N 3 C2H5 1939 O O C O- 1962 Cl N 1958 C2H5 7-chloroquinoline (synthesis intermediate found to display antibacterial activity) Nalidixic acid * a • typical chemical features of O O fluoroquinolones (a, b, c) BUT a naphthridone C - O- b (N at position 8: ) H C N N 3 • limited usefulness as drug C H 2 5 • narrow antibacterial spectrum c (Enterobacteriaceae only) • short half-life (1.5h) • high protein binding (90%) * Belg. pat. 612,258 to Sterling Drugs, 1962 From nalidixic acid to the 1st fluoroquinolone (1 of 4) nalidixic acid oxolinic acid * O O 1. modify naphthyridone O O into quinolone C - O C O O- O H3C N N N C2H5 C2H5 shows reduced protein binding... * Ger. pat. to Warner Lambert, 1967 * quinoleine From nalidixic acid to the 1st fluoroquinolone (1 of 4) nalidixic acid flumequine * 2. discovery of O O O O flumequine * C F C - O- O N H3C N N C2H5 CH3 shows weak but broad Gram(-) activity * Ger pat. to Rikker Labs, 1973 * benzo-quinolizine From nalidixic acid to the 1st fluoroquinolone (1 of 4) nalidixic acid pipemidic acid * O O O O 3. introduce a C - C - N O O piperazine * N N N H3C N N HN C2H5 C2H5 shows longer half-life... * Ger. Pat. to Roger Bellon, 1974 * pyrido-2-3-pyrimidine From nalidixic acid to the 1st fluoroquinolone (1 of 4) norfloxacin * combine all 3 O O nalidixic acid 2 features *... F C O- O O C - N O N HN 1 CH3 H3C N N C2H5 1978 3 broader Gram(-) activity less protein binding (50%) longer half-life (3-4h) * Belgian patent 863,429, 1978 to Kyorin * 6-fluoro-7-pyrimidino-quinoleine From norfloxacin to the other 1st generation fluoroquinolones: pefloxacin norfloxacin OO F C O- N N HN CH3 Add a methyl OO C to still increase F - O- half-life N N N CH3 CH 3 * Ger. pat. 2,840,910 to pefloxacin * Roger Bellon/Dainippon,1979 From norfloxacin to the other 1st generation fluoroquinolones: ofloxacin norfloxacin OO tricyclic compound F C (as in flumequine but - O morpholine ring) N N HN CH3 O O O O F C O-- F C O-- N N N N N O H3C N CH3 H3C CH3 pefloxacin ofloxacin* * Eur. pat. Appl. 47,005 to Daiichi, 1982 From norfloxacin to the other 1st generation fluoroquinolones: ciprofloxacin norfloxacin ciprofloxacin * O O F C cyclopropyl to O O O- increase potency F C O- N N HN N N CH3 HN O O O F C -- F O O C N N N N O-- N N O H C CH H3C 3 3 CH3 pefloxacin ofloxacin * Ger. pat. 3,142,854 to Bayer AG, 1983 "1st generation" fluoroquinolones norfloxacin ciprofloxacin O O O O F C - C O F - O N N N N HN HN CH3 cyclo piperazine propyl O O O O F C -- C O F - O- N N N N N N H3C CH3 O methyl H3C CH3 pefloxacin ofloxacin morpholine The "first generation" of fluoroquinolones 1960 1970 1980 t1/2 activity • Nalidixic acid • Norfloxacin 3-4 h ++ • Oxolinic acid • Pefloxacin 11 h + • Cinoxacin • Ofloxacin improved 6 h ++ • Pipemidic acid • Ciprofloxacin anti Gram (-) 3-4 h +++ activity • Fleroxacin • Rufloxacin From ofloxacin to levofloxacin... Ofloxacin is a racemic mixture O O C N F - O- H Levofloxacin is the pure (-) S isomer * N N O N O H3C CH3 CH3 The active form of ofloxacin is the (-) S isomer * Eur. pat. 206,283 to Daiichi, 1987 The present "first generation" of fluoroquinolones ... 1960 1970 1980 t1/2 activity • Nalidixic acid • Norfloxacin 3-4 h ++ • Oxolinic acid • Pefloxacin 11 h + • Flumequine • Ofloxacin improved 6 h ++ • Pipemidic acid • Ciprofloxacin anti Gram (-) 3-4 h +++ activity • Fleroxacin • Rufloxacin • Levofloxacin 6 h ++++ twice as active as ofloxacin per g How to improve the chemotherapeutic usefulness of the "first generation" fluoroquinolones 1. Maintain broad Gram(-) activity “2d generation” 2. Improve Gram(+) activity 3. Acquire activity against anaerobes “3d generation” The “second generation” fluoroquinolones 1960 1970 1980 1990 2000 a • Temafloxacin • Gram (-); • Sparfloxacin b • Grepafloxacin c • improved Gram (+) • Gatifloxacin d anti-anaerobe a: Toyama, 1988 (?) ; b: Dainippon, 1985-1987; c: Otskuda, 1989; d: Kyorin, 1988 The “third generation” fluoroquinolones 1960 1970 1980 1990 2000 • Clinafloxacin a • Trovafloxacin b anti-Gram (-) anti-Gram (+) • Moxifloxacin c anti-anaerobe • Gemifloxacin d a:Kyorin, 1987; b: Pfizer, 1993; c: Bayer, 1994; d: LG Chemical Ltd., S. Korea, 1994-98 1. maintenance of anti - Gram (-) activity Gram (-) NH2 R5 O F COOH piperazine N Gram (-) R7 C N N MIC R1 R bulky group Cl, F halogen MIC O-CH3 methoxy Gram (-) activity (E. coli) I II O O CH3 O O CH3 O O F C F C F C O- O- O- H3C H3C N N N N N N HN HN HN H 3 CO ciprofloxacin grepafloxacin gatifloxacin 0.125 - 0.5 0.06 - 2 0.06 2. improving Gram (+) activity (S. pneumoniae) Gram (+) CH3 R5 O pyrimidine F COOH N Gram (+) F H 2N R7 X8 N MIC F R1 bulky group N Gram (+) if X = C naphthyridone 8 Cl, F halogen MIC O-CH3 methoxy Activity against S. pneumoniae I II NH2 OO III O O F C F C O- O- H3C N N N N HN HN F H CO 3 H3C O O sparfloxacin moxifloxacin F C O- 0.125 - 0.5 0.01 - 0.5 CH3 O O O O N N HN F C F C O- O- H C 3 H N N N N N HN F F ciprofloxacin + H3N 0.5 - 2 H F F temafloxacin trovafloxacin 0.5 - 1 0.007 - 0.25 3. obtaining activity against anaerobes ... R5 O F COOH F R7 X8 N R1 F bulky group N if X8 = C naphthyridone O-CH3 methoxy Activity against B. fragilis OO CH3 O O I II III F C F C O- O- H3C N N N N HN HN H CO H 3 CO 3 O O F C gatifloxacin moxifloxacin O- 0.25 - 8 0.25 - 8 N N HN O O O O F C F C O- O- H ciprofloxacin N N N N N N N 2 - 128 F H3CO + H3N H CH HN2 2 gemifloxacin trovafloxacin F 0.5 - 64 0.125 - 8 Is there a SAR for emergence of resistance ? The "Mutant Prevention Concentration" * "When Mycobacterium bovis BCG and Staphylococcus aureus were plated on agar containing increasing concentrations of fluoroquinolone, colony numbers exhibited a sharp drop, followed by a plateau and a second sharp drop. The plateau region correlated,vith the presence of first-step resistant mutants. Mutants were not recovered at concentrations above those required for the second sharp drop, thereby defining a mutant prevention concentration (MPC). A C8-methoxy group lowered the MPC for an N-1-cyclopropyl fluoroquinolone" Is there a SAR for emergence of resistance ? Bactericidal activity of FQs against Mycobaterium bovis CH O O MIC (99) 3 F C - 1 O H5C2 N N 10-2 HN R 10-4 10-6 PD160793 PD161148 MPC (10) R = OCH3 R = H 10-8 Fraction of Fraction survivors 10-10 MIC 99 0.25 0.8 MPC 10 0.9 9 0.01 0.10 1.00 10.00 MPC/MIC 3.6 12 FQ concentration Dong et al; AAC 43:1756-1758 Fluoroquinolones with a C8-methoxy I II III O O CH3 O O O O F C F C F C O- O- O- H3C N N N N N N HN HN HN H CO H 3 CO 3 ciprofloxacingatifloxacin moxifloxacin Toxicity This is where all may fail... Frequent side effects of fluoroquinolones: is there a SAR ? COMPLEXATION WITH METALLIC IONS (Fe, Al, Mg, Ca) PHOTOTOXICITY DRUG INTERACTIONS: INHIBITION OF cyt P450 (1A2) ? CNS TOXICITY (BINDING TO GABA RECEPTOR) ? GASTRO-INTESTINAL DISCOMFORT ? CARTILAGE and MUSCULOSQUELETAL TOXICITY SAR of frequent side effects R R Ca++, Al+++, Fe++ N N complexation HN HN R Binding to R R5 O Penetration GABA receptor All FQs in CNS F COO- N R X N cipro, 7 8 grepa ... Inhibition of P450 R 1 sparflo, C flero, lomeflo F Inhibition of P450 Phototoxicity Fluoroquinolones with low or no drug interactions.. Trova O O Gati O O F C O- F C O- H H3C N N N N N F HN H + 3N H CO H 3 F O O Moxi Grepa CH3 O O F C O- F C O- N N HN H3C N N H CO 3 HN Fluoroquinolones with high phototoxicity ..
Load more

Recommended publications
  • A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of
    A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional.
    [Show full text]
  • The Effect of Chloramphenicol on BB88 Murine Erythroleukemia Cells
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 8-2007 The Effect of Chloramphenicol on BB88 Murine Erythroleukemia Cells Peter K. W. Harris Western Michigan University Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Chemistry Commons Recommended Citation Harris, Peter K. W., "The Effect of Chloramphenicol on BB88 Murine Erythroleukemia Cells" (2007). Dissertations. 872. https://scholarworks.wmich.edu/dissertations/872 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECT OF CHLORAMPHENICOL ON BB88 MURINE ERYTHROLEUKEMIA CELLS by Peter K. W. Harris A Dissertation Submitted to the Faculty o f The Graduate College in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Department of Biological Sciences Western Michigan University Kalamazoo, Michigan August 2007 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. THE EFFECT OF CHLORAMPHENICOL ON BB88 MURINE ERYTHROLEUKEMIA CELLS Peter K. W. Harris, Ph.D. Western Michigan University, 2007 DNA microarrays can be used to measure genome-wide transcript levels. These measurements may be useful in understanding cellular changes induced by a chemical agent. In this study, Affymetrix microarray technology has been used to study the effects of chloramphenicol, an antibiotic that inhibits bacterial and mitochondrial protein synthesis, on the transcription profile in mammalian cells. Transcript levels in BB88 murine erythroleukemia cells treated with 50 micromolar (pM) chloramphenicol, a concentration shown to inhibit BB 88 proliferation, are measured.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Fluoroquinolones in the Management of Acute Lower Respiratory Infection
    Thorax 2000;55:83–85 83 Occasional review Thorax: first published as 10.1136/thorax.55.1.83 on 1 January 2000. Downloaded from The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults Peter J Moss, Roger G Finch Lower respiratory tract infections (LRTI) are ing for up to 40% of isolates in Spain19 and 33% the leading infectious cause of death in most in the United States.20 In England and Wales developed countries; community acquired the prevalence is lower; in the first quarter of pneumonia (CAP) and acute exacerbations of 1999 6.5% of blood/cerebrospinal fluid isolates chronic bronchitis (AECB) are responsible for were reported to the Public Health Laboratory the bulk of the adult morbidity. Until recently Service as showing intermediate sensitivity or quinolone antibiotics were not recommended resistance (D Livermore, personal communi- for the routine treatment of these infections.1–3 cation). Pneumococcal resistance to penicillin Neither ciprofloxacin nor ofloxacin have ad- is not specifically linked to quinolone resist- equate activity against Streptococcus pneumoniae ance and, in general, penicillin resistant in vitro, and life threatening invasive pneumo- pneumococci are sensitive to the newer coccal disease has been reported in patients fluoroquinolones.11 21 treated for respiratory tract infections with Resistance to ciprofloxacin develops rela- these drugs.4–6 The development of new fluoro- tively easily in both S pneumoniae and H influ- quinolone agents with increased activity enzae, requiring only a single mutation in the against Gram positive organisms, combined parC gene.22 23 Other quinolones such as with concerns about increasing microbial sparfloxacin and clinafloxacin require two resistance to â-lactam agents, has prompted a mutations in the parC and gyrA genes.11 23 re-evaluation of the use of quinolones in LRTI.
    [Show full text]
  • Applications
    APPLICATIONS Zeshan Aqeel Senior Application Scientist A Screen of 22 Common Antibiotics that Demonstrates Zeshan loves to collect watches and the Back to the the Unique Reversed Phase Selectivity and Improved Future Trilogy. He has twin boys who drive him crazy! He Chromatographic Performance for Bases using a is an Apple Fanboy for life and ® he likes being in the lab more Kinetex PS C18 HPLC/UHPLC Column than anywhere else. Zeshan Aqeel, Jeff Layne, and Ryan Splitstone Phenomenex, Inc., 411 Madrid Ave, Torrance CA 90501 USA Overview Ciprofloxacin The Kinetex PS C18 is a USP classified L1 column, that provides Molecular Formula: C17H19FN3O3 both a unique polar/hydrophobic selectivity, and is 100 % aqueous Basic pKa: 8.77 stable. The column demonstrates enhanced selectivity and peak Acidic pKa: 5.56 shape for basic compounds under typical reversed phase condi- LogP: -0.86 tions. In addition, the solid support is a Kinetex core-shell (superfi- CH3 cially porous) particle morphology that provides ultra-high column + O S O 1 NH efficiency on any HPLC or UHPLC system. CH3 2 N N + O S O The mobile phase program chosen was a routine gradientNH of Acetonitrile with 0.1 % Formic Acid as the strong organic solvent2 and Water with 0.1 % Formic Acid as Nthe weak solvent.N The flow O F rate of 0.5 mL/min was used, and the column heater was set to ambient temperature (25 °C).O OH O F F OH Introduction OH O HO N In this application, 22 antibiotics were analyzed to demonstrate the F OH Kinetex PS C18 HPLC/UHPLC column’s unique multi-modal selec- F tivity and improved chromatographic performance for polar bases.
    [Show full text]
  • TROVAN® Tablets(Trovafloxacin Mesylate)
    TROVAN- trovafloxacin mesylate tablet, film coated TROVAN- trovafloxacin mesylate injection, solution, concentrate Roerig ---------- TROVAN® Tablets (trovafloxacin mesylate) TROVAN® I.V. (alatrofloxacin mesylate injection) For Intravenous Infusion TROVAN® HAS BEEN ASSOCIATED WITH SERIOUS LIVER INJURY LEADING TO LIVER TRANSPLANTATION AND/OR DEATH. TROVAN-ASSOCIATED LIVER INJURY HAS BEEN REPORTED WITH BOTH SHORT-TERM AND LONG-TERM DRUG EXPOSURE. TROVAN USE EXCEEDING 2 WEEKS IN DURATION IS ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF SERIOUS LIVER INJURY. LIVER INJURY HAS ALSO BEEN REPORTED FOLLOWING TROVAN RE- EXPOSURE. TROVAN SHOULD BE RESERVED FOR USE IN PATIENTS WITH SERIOUS, LIFE- OR LIMB-THREATENING INFECTIONS WHO RECEIVE THEIR INITIAL THERAPY IN AN IN-PATIENT HEALTH CARE FACILITY (I.E., HOSPITAL OR LONG-TERM NURSING CARE FACILITY). TROVAN SHOULD NOT BE USED WHEN SAFER, ALTERNATIVE ANTIMICROBIAL THERAPY WILL BE EFFECTIVE. (SEE WARNINGS.) TROVAN is available as TROVAN Tablets (trovafloxacin mesylate) for oral administration and as TROVAN I.V. (alatrofloxacin mesylate injection), a prodrug of trovafloxacin, for intravenous administration. DESCRIPTION TROVAN Tablets TROVAN Tablets contain trovafloxacin mesylate, a synthetic broad-spectrum antibacterial agent for oral administration. Chemically, trovafloxacin mesylate, a fluoronaphthyridone related to the fluoroquinolone antibacterials, is (1α, 5α, 6α)-7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4- difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, monomethanesulfonate. Trovafloxacin mesylate differs from other quinolone derivatives by having a 1,8-naphthyridine nucleus. The chemical structure is: Its empirical formula is C20H15F3N4O3•CH3SO3H and its molecular weight is 512.46. Trovafloxacin mesylate is a white to off-white powder.
    [Show full text]
  • Disabling and Potentially Permanent Side Effects Lead to Suspension Or Restrictions of Quinolone and Fluoroquinolone Antibiotics
    16 November 2018 EMA/795349/2018 Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics EMA has reviewed serious, disabling and potentially permanent side effects with quinolone and fluoroquinolone antibiotics given by mouth, injection or inhalation. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018. EMA’s human medicines committee (CHMP) has endorsed the recommendations of EMA’s safety committee (PRAC) and concluded that the marketing authorisation of medicines containing cinoxacin, flumequine, nalidixic acid, and pipemidic acid should be suspended. The CHMP confirmed that the use of the remaining fluoroquinolone antibiotics should be restricted. In addition, the prescribing information for healthcare professionals and information for patients will describe the disabling and potentially permanent side effects and advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or joints and the nervous system. Restrictions on the use of fluoroquinolone antibiotics will mean that they should not be used: • to treat infections that might get better without treatment or are not severe (such as throat infections); • to treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis; • for preventing traveller’s diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder); • to treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used. Importantly, fluoroquinolones should generally be avoided in patients who have previously had serious side effects with a fluoroquinolone or quinolone antibiotic.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides
    Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides a, b,c Luke F. Chen, MBBS (Hons), MPH, CIC, FRACP *, Donald Kaye, MD KEYWORDS Rifaximin Pharmacokinetics Pharmacodynamics Toxicity Polymyxins Aminoglycoside Rifampin The polymyxins, rifamycins, and the aminoglycosides may be considered special use antibacterial agents. They are all old agents and are rarely considered the drugs of choice for common bacterial infections. The polymyxins are increasingly important because of the continued emergence of multidrug resistant (MDR) gram-negative organisms, such as strains of Pseudomonas aeruginosa or carbapenemase-producing Enterobacteriaceae that are susceptible to few remaining drugs. Rifampin is only considered in the context of nonmycobacterial infections where its role is limited and sometimes controversial. Rifaximin is a new enteric rifamycin that is increasingly used for gastrointestinal infections such as trav- eler’s diarrhea and Clostridium difficile infections (CDIs). This article will also review the current role of aminoglycosides in nonmycobacterial systemic infections, with an emphasis on the use of single daily administration. POLYMYXINS The polymyxins were discovered in 1947. Although there are five known polymyxin molecules, sequentially named polymyxin A through polymyxin E, only two polymyxins are available for therapeutic use: polymyxin B and polymyxin E (colistin) (Table 1). Both polymyxin B and polymyxin E are large cyclic cationic polypeptide detergents A version of this article appeared in the 23:4 issue of the Infectious Disease Clinics of North America. a Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Box 102359, Hanes House, Durham, NC 27710, USA b Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA c 1535 Sweet Briar Road, Gladwyne, PA 19035, USA * Corresponding author.
    [Show full text]
  • The Grohe Method and Quinolone Antibiotics
    The Grohe method and quinolone antibiotics Antibiotics are medicines that are used to treat bacterial for modern fluoroquinolones. The Grohe process and the infections. They contain active ingredients belonging to var- synthesis of ciprofloxacin sparked Bayer AG’s extensive ious substance classes, with modern fluoroquinolones one research on fluoroquinolones and the global competition of the most important and an indispensable part of both that produced additional potent antibiotics. human and veterinary medicine. It is largely thanks to Klaus Grohe – the “father of Bayer quinolones” – that this entirely In chemical terms, the antibiotics referred to for simplicity synthetic class of antibiotics now plays such a vital role for as quinolones are derived from 1,4-dihydro-4-oxo-3-quin- medical practitioners. From 1965 to 1997, Grohe worked oline carboxylic acid (1) substituted in position 1. as a chemist, carrying out basic research at Bayer AG’s Fluoroquinolones possess a fluorine atom in position 6. In main research laboratory (WHL) in Leverkusen. During this addition, ciprofloxacin (2) has a cyclopropyl group in posi- period, in 1975, he developed the Grohe process – a new tion 1 and also a piperazine group in position 7 (Figure A). multi-stage synthesis method for quinolones. It was this This substituent pattern plays a key role in its excellent achievement that first enabled him to synthesize active an- antibacterial efficacy. tibacterial substances such as ciprofloxacin – the prototype O 5 O 4 3 6 COOH F COOH 7 2 N N N 8 1 H N R (1) (2) Figure A: Basic structure of quinolone (1) (R = various substituents) and ciprofloxacin (2) Quinolones owe their antibacterial efficacy to their inhibition This unique mode of action also makes fluoroquinolones of essential bacterial enzymes – DNA gyrase (topoisomer- highly effective against a large number of pathogenic ase II) and topoisomerase IV.
    [Show full text]
  • Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
    SURVEILLANCE REPORT SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe in Europe consumption of antimicrobial Surveillance Surveillance of antimicrobial consumption in Europe 2013-2014 2012 www.ecdc.europa.eu ECDC SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe 2013–2014 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Klaus Weist. Contributing authors Klaus Weist, Arno Muller, Ana Hoxha, Vera Vlahović-Palčevski, Christelle Elias, Dominique Monnet and Ole Heuer. Data analysis: Klaus Weist, Arno Muller and Ana Hoxha. Acknowledgements The authors would like to thank the ESAC-Net Disease Network Coordination Committee members (Marcel Bruch, Philippe Cavalié, Herman Goossens, Jenny Hellman, Susan Hopkins, Stephanie Natsch, Anna Olczak-Pienkowska, Ajay Oza, Arjana Tambić Andrasevic, Peter Zarb) and observers (Jane Robertson, Arno Muller, Mike Sharland, Theo Verheij) for providing valuable comments and scientific advice during the production of the report. All ESAC-Net participants and National Coordinators are acknowledged for providing data and valuable comments on this report. The authors also acknowledge Gaetan Guyodo, Catalin Albu and Anna Renau-Rosell for managing the data and providing technical support to the participating countries. Suggested citation: European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2013‒2014. Stockholm: ECDC; 2018. Stockholm, May 2018 ISBN 978-92-9498-187-5 ISSN 2315-0955
    [Show full text]
  • Duration of Antibiotic Treatment for Uncomplicated Urinary Tract Infection in Long-Term Care Residents
    EVIDENCE BRIEF Duration of Antibiotic Treatment for Uncomplicated Urinary Tract Infection in Long-Term Care Residents October 2018 Key Messages Recent evidence suggests that short courses of antibiotics (7 days or less) are appropriate for older adults with uncomplicated lower urinary tract infections. There are several advantages to short course antibiotic therapy when compared to longer durations, including less side effects,1,2 less risk of antibiotic-resistant organisms3,4 and less risk of C. difficile infection.5 Duration of Antibiotic Treatment for Uncomplicated UTI in Long-Term Care Residents 1 Issue and Research Question Overuse of antimicrobial therapy in the long term care (LTC) setting is common and leads to patient harm.6 Seventy eight (78) % of Ontario LTC residents will receive at least one course of antimicrobial therapy over the course of a year. Of these prescriptions, one third are prescribed for urinary indications. At least one- third of these prescriptions are for asymptomatic bacteriuria, a condition that does not benefit from antimicrobial treatment in older adults.7 Sixty three (63) % of prescribed courses of antibiotic treatment in LTC are longer than 10 days. Duration of therapy varies drastically based on prescriber, but not patient characteristics.8 This overall long duration and prescriber variability persists when examining management of urinary tract infections. This data suggests that habit and experience play a large role in antibiotic prescribing patterns in long-term care, particularly for urinary tract infections. Due to the increased susceptibility to UTIs in older individuals, a function of reduced immune response and altered bladder function, elderly are often treated with longer antibiotic courses than younger patients.9 However, there is a lack of data that support the concept that longer courses are superior in this population.
    [Show full text]